A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer
Results from the CAPItello-291 study showed that capivasertib plus fulvestrant compared with placebo plus fulvestrant improved progression-free survival in participants with HR-positive/ HER2-negative advanced breast cancer whose cancer had grown or spread despite hormone therapy (with/without a CDK4/6 inhibitor).<b>Clinical Trial Registration:</b> NCT04305496 (CAPItello-291) (ClinicalTrials.gov).
Authors
- Eriko Tokunaga (ORCID: https://orcid.org/0000-0002-1640-5315)
- Gaia Schiavon (ORCID: https://orcid.org/0000-0001-9059-8971)
- Sacha J. Howell (ORCID: https://orcid.org/0000-0001-8141-6515)
- Петр Владимирович Криворотько (ORCID: https://orcid.org/0000-0002-4898-9159)
- Joohyuk Sohn (ORCID: https://orcid.org/0000-0002-2303-2764)
- Lynda Grinsted
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- Henry Gómez (ORCID: https://orcid.org/0000-0002-3415-9701)
- Javier Cortés (ORCID: https://orcid.org/0000-0001-7623-1583)
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Florence Dalenc (ORCID: https://orcid.org/0000-0002-9854-4182)
- Nicholas C. Turner (ORCID: https://orcid.org/0000-0001-8937-0873)
- Lyudmila Zhukova (ORCID: https://orcid.org/0000-0003-4848-6938)
- Xichun Hu (ORCID: https://orcid.org/0000-0001-6148-9186)
- Serafin M. Morales (ORCID: https://orcid.org/0000-0001-7445-4193)
- Andrew Foxley (ORCID: https://orcid.org/0009-0002-4166-2310)
- Sibylle Loibl (ORCID: https://orcid.org/0000-0001-6488-4958)
- Samih Yousef
- Hope S. Rugo (ORCID: https://orcid.org/0000-0001-6710-4814)
- Masakazu Toi (ORCID: https://orcid.org/0000-0003-1488-9958)
- Yeon Hee Park
- Elza de Bruin
Institutions
- AstraZeneca (United Kingdom) (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Institute of Cancer Research (GB)
- University of California, San Francisco (US)
- Yonsei University (KR)
- Cornell University (US)
- Emek Medical Center (IL)
- Samsung Medical Center (KR)
- Moscow Clinical Scientific Center (RU)
- Fudan University Shanghai Cancer Center (CN)
- National Hospital Organization Kyushu Cancer Center (JP)
- MedSIR (Spain) (ES)
- Institute of Oncology NN Petrov (RU)
- Universidad Ricardo Palma (PE)
- Royal Marsden Hospital (GB)
- Institute for Research in Biomedicine (ES)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- Vall d'Hebron Hospital Universitari (ES)
- Institut Claudius Regaud (FR)
- German Breast group (DE)
- The Christie NHS Foundation Trust (GB)
- Kyoto University Hospital (JP)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Vall d'Hebron Institute of Oncology (ES)
- Sungkyunkwan University (KR)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1080/14796694.2024.2390791
- Citations
- 5
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 2.09